Metabolomic profiling in LRRK2-related Parkinson's disease

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Johansen, Krisztina K ^a,b   Wang, Lei ^c,d   Aasly, Jan O ^a,b   White, Linda R ^a,b   Matson, Wayne R ^c   Henchcliffe, Claire ^d   Beal, M Flint ^d   Bogdanov, Mikhail ^c,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT; HYPOXANTHINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; NEUROLEPTIC AGENT; PURINE; SELEGILINE; URIC ACID; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOSITY; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; NUCLEIC ACID ANALYSIS; PARKINSON DISEASE; PLASMA; URIC ACID BLOOD LEVEL; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOXANTHINE; MALE; METABOLOMICS; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; URIC ACID;

EID: 70449552850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007551     Document Type: Article

References (40)

1. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (2006) Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60: 389-398.
2. Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69: 2093-2104.
3. Schiesling C, Kieper N, Seidel K, Kruger R (2008) Review: Familial Parkinson's disease-genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 34: 255-271.
4. Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16 Spec No. 2: R183-194.
5. Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, et al. (2005) G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord 20: 1653-1655.
6. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, et al. (2005) G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58: 784-787.
7. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354: 424-425.
8. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, et al. (2005) Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 57: 762-765.
9. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, et al. (2000) SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 247 Suppl 4: IV/2-7.
10. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, et al. (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17: 303-312.
11. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, et al. (1992) Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42: 2111-2117.
12. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J 20: 419-425.
13. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349: 162-166.
14. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, et al. (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396.
15. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104: 955-960.
16. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB (2004) Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 22: 245-252.
17. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, et al. (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8: 1439-1444.
18. Griffin JL, Nicholls AW (2006) Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics 7: 1095-1107.
19. Di Leo A, Claudino W, Colangiuli D, Bessi S, Pestrin M, et al. (2007) New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann Oncol 18 Suppl 12: xii8-14.
20. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, et al. (2006) Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 3: e327.
21. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, et al. (2005) Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1: 101-108.
22. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, et al. (2006) Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129: 877-886.
23. Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, et al. (2006) LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 12: 410-419.
24. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, et al. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128: 2786-2796.
25. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56: 33-39.
26. Kristal BS, Vigneau-Callahan KE, Matson WR (1998) Simultaneous analysis of the majority of low-molecular-weight, redox-active compounds from mitochondria. Anal Biochem 263: 18-25.
27. Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS (2002) Attention to relative response across sequential electrodes improves quantitation of coulometric array. Anal Biochem 302: 239-245.
28. Vigneau-Callahan KE, Shestopalov AI, Milbury PE, Matson WR, Kristal BS (2001) Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats. J Nutr 131: 924S-932S.
29. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, Matson WR (1999) Purine catabolism: links to mitochondrial respiration and antioxidant defenses? Arch Biochem Biophys 370: 22-33.
30. Eriksson L, Johansson E, Kettanah-Wold N, Wold S (2001) Multi- and megavariate data analysis: Sweden: Umetrics AB, Malmo.
31. Broadhurst DI, Kell DB (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2: 171-196.
32. Rubingh CM, Bijlsma S, Derks EPPA, Bobeldijk I, Verheij ER, et al. (2006) Assessing the performance of statistical validation tools megavariate metabolomics data. Metabolomics 2: 53-61.
33. Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, et al. (2008) Assessment of PLSDA cross validation. Metabolomics 4: 81-89.
34. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-590.
35. Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson's disease. Mov Disord 22: 1133-1137.
36. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58: 797-800.
37. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, et al. (2009) Urate predicts rate of clinical decline in Parkinson disease. Arch Neurol.
38. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, et al. (2008) Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 167: 831-838.
39. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, et al. (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65: 716-723.
40. Gamache PH, Meyer DF, Granger MC, Acworth IN (2004) Metabolomic applications of electrochemistry/mass spectrometry. J Am Soc Mass Spectrom 15: 1717-1726.